Key facts
- This page summarizes Jean Bennett's Form 4 filing for REGENXBIO Inc. (RGNX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Jun 2024, 16:41.
Jean Bennett - 31 May 2024 Form 4 Insider Report for REGENXBIO Inc. (RGNX)
- Reporting relationship
- Director
- Issuer ticker
- RGNX
- Reported as of
- 31 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jun 2024, 16:41:53 UTC
- Prior SEC filing
- 06 Jun 2023
- Next SEC filing
- 24 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick J. Christmas as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jean Bennett filed Form 4 for REGENXBIO Inc. (RGNX) on 04 Jun 2024.
Change
- Previous filing in this sequence was filed on 06 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RGNX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,790
- Change %
- +74%
- Price
- $0.000000
- Shares after
- 11,286
- Date
- 31 May 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RGNX
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +24,454
- Change %
- Price
- $0.000000
- Shares after
- 24,454
- Date
- 31 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,454
- Exercise price
- $14.35
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2025 subject to the continuous service of the recipient to the Issuer.
Footnote F2
The option will vest in 12 equal monthly installments following May 31, 2024 subject to the continuous service of the optionee to the Issuer.